Ark Biosciences' Anti-RSV AK0529 Successfully Completes Phase I Study
Ark Biosciences announced the successful completion of phase 1 clinical study of its anti-respiratory syncytial virus (RSV) drug AK0529.
know more >
Ark Biosciences Completes Series A Financing and Reports Significant Progress for AK0529
Ark Biosciences announced successful completion of a Series A financing.
know more >